Sorrento Therapeutics, Inc. (SRNE) SEC Filing 8-K Material Event for the period ending Tuesday, October 1, 2019

Sorrento Therapeutics, Inc.

CIK: 850261 Ticker: SRNE

View differences made from one to another to evaluate Sorrento Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Sorrento Therapeutics, Inc..


Assess how Sorrento Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Sorrento Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Sorrento Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: SRNE
CIK: 850261
Form Type: 8-K Corporate News
Accession Number: 0001144204-19-046767
Submitted to the SEC: Tue Oct 01 2019 4:32:53 PM EST
Accepted by the SEC: Tue Oct 01 2019
Period: Tuesday, October 1, 2019
Industry: Commercial Physical And Biological Research
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: